Mr. Craig  Erlich

Chief Growth Officer

Mr. Josh  Bratton

Director of Development

Mr. Joel N. Agree J.D.

President, Chief Executive Officer & Director

Ms. Danielle M. Spehar J.D.

General Counsel

Mr. Reuben Goldman Treatman CPA

Senior Director of Corporate Finance

Mr. Peter  Coughenour

Chief Financial Officer, Secretary & Investor Relations Professional

Mr. Larry  Kaufman

Chief Information Officer & Vice President of Continuous Improvement

Mr. Richard A. Agree

Executive Chairman of the Board

Ms. Nicole  Witteveen

Chief Operating Officer

Mr. Stephen  Breslin

Chief Accounting Officer

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter and year ended December 31, 2024, and provide operational updates.

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

Dividend stocks offer a reliable way to generate monthly income without the hassles of finding a side gig, buying and managing a rental property, or any other things you learn about while doom-scrolling social media these days.

These 5 Dividend Stocks Will Pay You Like a Boss Every Month

Currently, we have many signs pinpointing to a value factor outperforming growth. It seems that the dividend-oriented stocks might become the new glamour. In this article, I elaborate on the key reasons why I think so. I highlight 3 specific high and durable yield segments that could really deliver superior returns going.

Dividends Come Back Into Vogue: My Favorite Places For Income Extraction

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Screen size too small

$75.60

Grades

Key Facts

Competitors